9 results about "Meibomian gland dysfunction" patented technology

This invention discloses the application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome, relating to the field of biomedical technology. The application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome. This invention is the first to discover the application of the Wnt-β-catenin pathway inhibitor LGK974 in the treatment of dry eye syndrome. LGK974, by inhibiting the Wnt-β-catenin pathway, can effectively protect meibomian gland acini and ducts, restoring normal lipid metabolism and secretion. In a NOD (Normally Ophthalmic Disorder) Sjögren's syndrome model, oral administration of 200-400 μg / kg / day of LGK974 significantly improved dry eye symptoms, including reduced corneal defects and increased tear secretion, alleviating morphological and functional damage to the meibomian glands. LGK974 provides a new targeted strategy for the treatment of dry eye syndrome, especially Sjögren's syndrome-related dry eye syndrome and meibomian gland dysfunction-related dry eye syndrome, and may become a potent and effective drug for the clinical treatment of dry eye in the future.

This invention discloses a multi-dimensional quantitative assessment method and system combining meibomian gland morphology and function, belonging to the fields of ophthalmic diagnosis and artificial intelligence technology. It acquires color images of the eyelid margin, infrared images of the meibomian glands, and dynamic videos of gland expulsion upon pressure, inputting these into a dedicated AI analysis engine for processing. Employing an innovative anatomically guided backbone network and a meibomian gland region adaptive module, it achieves parallel automatic quantitative scoring across four dimensions: meibomian gland opening abnormality score, secretion characteristics score, expulsion capacity score, and morphological abnormality score based on gland segmentation loss rate. The four scores are summed to obtain a comprehensive total score, used for the graded diagnosis of meibomian gland dysfunction. By comparing changes in the patient's scores over time, it achieves macroscopic and microscopic evaluation of treatment efficacy. By integrating functional and morphological indicators into a unified automated quantitative system, it solves the problems of subjectivity and fragmentation in existing assessment methods, significantly improving the objectivity, comprehensiveness, and accuracy of diagnosis, and providing a reliable tool for individualized treatment and long-term management of MGD.

The utility model relates to meibomian gland dysfunction treatment technical field, especially for a kind of treatment device of meibomian gland dysfunction, including two groups of left-right symmetrical distribution's outer shell, the front end of the outer shell and along the rim place is wrapped with soft silica gel strip, the front end of the outer shell is connected with treatment eyecup, the inside of the treatment eyecup is evenly provided with steam outlet, the front end of the treatment eyecup outside is connected with sealing baffle, the outside of two groups the outer shell and towards the end of one end is connected with adjusting band, in the utility model, can carry out the sustained steam hot compress to eye, can be expanded meibomian gland opening by hot compress, improve secretion discharge, compared with towel, it is more convenient and fast, and can be adjusted according to eye interval, also can select single eye and double eye hot compress treatment, convenient to use, improve treatment efficiency.

This invention provides a treatment device for meibomian gland dysfunction, relating to the field of medical device technology. It addresses the technical problem that existing eyelid heating treatment devices can only achieve eyelid heating or require the administration of symptomatic medication before initiating heating treatment, failing to achieve simultaneous heating and medication action. The device includes a frame, shaped like an eyeglass frame, for the patient to wear; temples for fitting the frame around the patient's ears; a heating mechanism fixedly mounted on the frame, comprising a heating plate and heating cotton; the heating plate and heating cotton being fixedly mounted on the frame and conforming to the outer side of the patient's eyelid; and an atomizing mechanism for spraying atomized medication from the inside of the temples onto the patient's eyelid corresponding to the heating cotton. Through the eyeglass-frame-like frame, temples, and integrated heating and atomizing mechanisms, heating and medication are simultaneously administered, achieving integrated and synergistic treatment and improving efficacy.

1. The name of the design product: Eversion device. 2. The use of the design product: For the diagnosis of dry eye and meibomian gland dysfunction. 3. The design points of the design product: In shape. 4. The picture or photo that best indicates the design points: Design 1 perspective view 1. 5. Design 1 is designated as the basic design.

Described herein are methods for the manufacture of compositions useful for the treatment of meibomian gland dysfunction. Said methods utilize rheological properties of petrolatum induced by a high shear mixing feature of the method. The products of the methods of manufacture described herein are stable anhydrous composition of selenium disulfide which are substantially free of selenium disulfide agglomerates and degradation products.

The present invention provides a Lotilaner-containing microemulsion eye drop, a preparation method therefor, and a use thereof in eye diseases such as demodex blepharitis, ocular rosacea, and meibomian gland dysfunction.

The application discloses application of a Piezo1 agonist in preparation of a medicine for treating meibomian gland dysfunction, and belongs to the technical field of biological medicines. The application first proposes Piezo1 as a brand-new medicine target for treating meibomian gland dysfunction. Experiments prove that the Piezo1 agonist can directly target the meibomian gland, effectively enhance the glycolysis level of cells, and then promote cell differentiation and lipid synthesis, so as to restore the gland function and treat meibomian gland dysfunction. The application provides a brand-new thought and strategy for research and development of a medicine for treating meibomian gland dysfunction, and has a wide clinical application prospect.

This invention provides a semi-fluorinated alkane eye drop containing loteranal and its preparation method, as well as its application in eye diseases such as Demodex blepharitis, ocular erythema acne, and meibomian gland dysfunction.